Home
News
- 1 MRNA stock price prepares to reach $200 amid its bird flu preparation.
- 2 The company announced phase 2 data for its investigational personalized cancer vaccine.
- 3 Moderna’s vaccine technology is already a step ahead for future diseases.
MRNA stock price prepares for a robust rally, targeting $200, as it prepares to produce hundreds of millions of bird flu shots, if needed. According to Reuters, leading vaccine maker firms claim to be prepared to produce millions of bird flu vaccine shots. The shots are meant for humans and can be produced within months, if a new strain of Avian Influenza ever jumps crossing the species.
The stock price can soon witness a bull run, as Moderna Inc., is already on execution for human trials of the vaccine samples, which can better match the circulating subtype. Moderna Inc. is taking a precautionary measure against a future pandemic. Per its new approach, in crisis situations, vaccine manufacturers will shift production of seasonal flu vaccines and instead make tailor-made shots to the new outbreak, when needed.
Moderna Always a Step Ahead
As Moderna disclosed, many of its potential pandemic vaccine shots are pre-approved by the concerned authorities. Based on the released data from human trials, the shots are safe for human use and prompt an immune reflex. This implies that Moderna might not require further human trials, even if they have to be tweaked to adapt to the strain that jumps to humans.
Experts have long advocated for the new approach in developing flu vaccines for both seasonal and pandemic flu. COVID proved Moderna’s mRNA technology’s potential to adapt to changing viruses. Along the similar lines, Moderna announced phase 2 data on MRNA-4157/V940. It is an investigational mRNA personalized cancer vaccine, which will be presented at the 2023 AACR annual meeting.
According to a press release, Moderna Inc.’s two abstracts of the investigational cancer vaccine have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting. The AACR meeting is scheduled for mid-April in Orlando, Florida. Personalized cancer vaccines are created to enhance the immune system so that a patient can generate a required anti-tumor response, forced by their tumor mutation signature.
MRNA Stock Price Action
MRNA stock price escaped the falling regression channel and hinted at a possible rally. The stock price may witness a rally on successful presentation at AACR meeting. The volume shows a highly volatile market and suggests buyers gaining dominance. The EMA ribbon shows a possibility of forming a golden cross soon, giving MRNA stock price a bullish momentum. The Fib retracement levels show price to cross the first levels and enter the second level.
The projected rally may face resistance near $ 179.23, after which it may slightly consolidate. Once the resistance is breached, it may surge beyond $200. The anticipated move may take some time, but once established can act as a major support. The RSI rises close to the half line, indicating buyer’s influencing the price movement. The MACD forms a positive cross and records buyer interaction. The indicators show bullish signals and favor MRNA stock price movement.
Conclusion
MRNA stock price prepares to reach $200 soon. Its recent development regarding bird flu vaccine and personalized cancer vaccine, can bolster the predicted rally. The price surge is in its initial stages, but can strengthen once the AACR meeting ends well. The holder of MRNA can trust the support level near $133.74, and wait for it to break out of the current level.
Technical levels
Support levels: $133.74 and $117.10
Resistance levels: $179.23 and $207.50
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational purposes only, and they do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.
Nancy J. Allen is a crypto enthusiast, with a major in macroeconomics and minor in business statistics. She believes that cryptocurrencies inspire people to be their own banks, and step aside from traditional monetary exchange systems. She is also intrigued by blockchain technology and its functioning. She frequently researches, and posts content on the top altcoins, their theoretical working principles and technical price predictions.
